Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus ERYC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus ERYC.
AZASITE vs ERYC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic